Earlier today, Nutra Pharma Corporation (OTCQB: NPHC), the
company behind innovative pharmaceutical products such as Nyloxin® and Pet
Pain-Away, released a letter to shareholders. In the letter, Rik J. Deitsch,
the company’s chief executive officer, gave investors a brief overview of Nutra
Pharma’s progress during 2015, as well as its goals and expectations for the
coming months.
“We have had a very busy year at Nutra Pharma,” Deitsch
explained in the news release. “2015 has been an inflection year for the
company, launching our first new product in over two years (Pet Pain-Away),
allowing us to begin to get back into clinical research on our lead drug
candidates and bringing our drug platform into focus with the granting of
orphan designation for RPI-78M for the treatment of pediatric multiple
sclerosis.”
Among the most exciting news for Nutra Pharma’s prospective
investors was the company’s progress with its therapeutic drug pipeline. In
September, the company received orphan status for drug candidate RPI-78M for
the treatment of pediatric multiple sclerosis, an indication with no approved
treatments currently on the market. In addition to clearing the way for reduced
costs and an accelerated development timeline, orphan designation provides
Nutra Pharma with a seven-year period of market exclusivity in the U.S.
following FDA approval. In an effort to maximize the benefits of this program,
the company has also applied for orphan status for RPI-78M for the treatment of
Myasthenia Gravis (MG). After receiving this status, Nutra Pharma expects to
initiate clinical trials by the end of 2016.
In addition to its work on the drug development front, Nutra
Pharma continues to make progress toward expanding its retail distribution
network for its over-the-counter products. Sales from Nyloxin and Pet Pain-Away
are expected to bring in additional revenue for the company that will be
essential to the financing of proposed clinical studies. Nutra Pharma has
already announced plans to begin distribution of Nyloxin in Canada in the
coming months, and the company has also received acceptance from CPAM, the
medical authority in China, to expand its distribution network into the Asian
nation.
By reinitiating clinical work for its lead drug candidates,
RPI-MN and RPI-78M, Nutra Pharma is once again progressing toward its goal of
marketing or licensing its drugs for the treatment of multiple sclerosis and
HIV/AIDS. As it aims to meet its true potential in the bio-pharmaceutical
space, the company represents an intriguing option for investors in the coming
months.
The shareholder letter is available on the company’s website
at http://www.nutrapharma.com/Dec2015_shareholder_letter.pdf
For more information on the company, visit
www.NutraPharma.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment